The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma

Oncology Research

Volumn 20, Issue 4, 2012, Pages 139-147

  Zhang, Wen Hui ^a,b   Gui, Jun Hao ^a   Wang, Chang Zheng ^a   Chang, Qing ^a   Xu, Shi Ping ^a   Cai, Chang Hao ^a   Li, Ying Nan ^a   Tian, Ya Ping ^a   Yan, Li ^a   Wu, Ben Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

Biomarker; Distal gastric adenocarcinoma (DGAC); MicroRNAs; miR 375; Serum

Indexed keywords

MICRORNA 18B; MICRORNA 196B; MICRORNA 204; MICRORNA 375; MICRORNA 93; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DISTAL GASTRIC ADENOCARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA;

EID: 84871869117     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13522227232156     Document Type: Article

References (31)

1. Parkin, D. M. International variation. Oncogene 23(38):6329-6340; 2004.
2. Parkin, D. M.; Bray, F. I.; Devesa, S. S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37(Suppl. 8):S4-66; 2001.
3. Lauren, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64:31-49; 1965.
4. McColl, K. E. Cancer of the gastric cardia. Best Pract. Res. Clin. Gastroenterol. 20(4):687-696; 2006.
5. Devesa, S. S.; Blot, W. J.; Fraumeni, Jr., J. F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83(10):2049-2053; 1998.
6. Ambros, V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 113(6):673-676; 2003.
7. Furuta, M.; Kozaki, K. I.; Tanaka, S.; Arii, S.; Imoto, I.; Inazawa, J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(5):766-776; 2010.
8. Connolly, E.; Melegari, M.; Landgraf, P.; Tchaikovskaya, T.; Tennant, B. C.; Slagle, B. L.; Rogler, L. E.; Zavolan, M.; Tuschl, T.; Rogler, C. E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 173(3):856-864; 2008.
9. Raponi, M.; Dossey, L.; Jatkoe, T.; Wu, X.; Chen, G.; Fan, H.; Beer, D. G. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69(14):5776-5783; 2009.
10. Wang, Q. Z.; Xu, W.; Habib, N.; Xu, R. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr. Cancer Drug Targets 9(4):572-594; 2009.
11. Melkamu, T.; Zhang, X.; Tan, J.; Zeng, Y.; Kassie, F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31(2):252-258; 2010.
12. Lowery, A. J.; Miller, N.; Devaney, A.; McNeill, R. E.; Davoren, P. A.; Lemetre, C.; Benes, V.; Schmidt, S.; Blake, J.; Ball, G. and others. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11(3):R27; 2009.
13. Yan, L. X.; Huang, X. F.; Shao, Q.; Huang, M. Y.; Deng, L.; Wu, Q. L.; Zeng, Y. X.; Shao, J. Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11):2348-2360; 2008.
14. Schaefer, A.; Jung, M.; Mollenkopf, H. J.; Wagner, I.; Stephan, C.; Jentzmik, F.; Miller, K.; Lein, M.; Kristiansen, G.; Jung, K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126(5):1166-1176; 2010.
15. Schetter, A. J.; Leung, S. Y.; Sohn, J. J.; Zanetti, K. A.; Bowman, E. D.; Yanaihara, N.; Yuen, S. T.; Chan, T. L.; Kwong, D. L.; Au, G. K. and others. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4):425-436; 2008.
16. Liu, T.; Tang, H.; Lang, Y.; Liu, M.; Li, X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 273(2):233-242; 2009.
17. Tsukamoto, Y.; Nakada, C.; Noguchi, T.; Tanigawa, M.; Nguyen, L. T.; Uchida, T.; Hijiya, N.; Matsuura, K.; Fujioka, T.; Seto, M. and others. MicroRNA-375 is down-regulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 70(6):2339-2349; 2010.
18. Gui, J.; Tian, Y.; Wen, X.; Zhang, W.; Zhang, P.; Gao, J.; Run, W.; Tian, L.; Jia, X.; Gao, Y. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. (Lond.) 120(5):183-193; 2011.
19. Schmittgen, T. D.; Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6):1101-1108; 2008.
20. Chen, C.; Ridzon, D. A.; Broomer, A. J.; Zhou, Z.; Lee, D. H.; Nguyen, J. T.; Barbisin, M.; Xu, N. L.; Mahuvakar, V. R.; Andersen, M. R. and others. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33(20):e179; 2005.
21. Gulmann, C.; Hegarty, H.; Grace, A.; Leader, M.; Patchett, S.; Kay, E. Differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via the retinoblastoma pathway. World J. Gastroenterol. 10(1):17-21; 2004.
22. Taback, B.; Hoon, D. S. Circulating nucleic acids in plasma and serum: Past, present and future. Curr. Opin. Mol. Ther. 6(3):273-278; 2004.
23. Chan, K. C.; Lo, Y. M. Circulating tumour-derived nucleic acids in cancer patients: Potential applications as tumour markers. Br. J. Cancer 96(5):681-685; 2007.
24. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105(30):10513-10518; 2008.
25. Wang, J.; Chen, J.; Chang, P.; LeBlanc, A.; Li, D.; Abbruzzesse, J. L.; Frazier, M. L.; Killary, A. M.; Sen, S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. 2(9):807-813; 2009.
26. Tsujiura, M.; Ichikawa, D.; Komatsu, S.; Shiozaki, A.; Takeshita, H.; Kosuga, T.; Konishi, H.; Morimura, R.; Deguchi, K.; Fujiwara, H. and others. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 102(7):1174-1179; 2010.
27. Mathe, E. A.; Nguyen, G. H.; Bowman, E. D.; Zhao, Y.; Budhu, A.; Schetter, A. J.; Braun, R.; Reimers, M.; Kumamoto, K.; Hughes, D.; et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin. Cancer Res. 15(19):6192-6200; 2009.
28. Ladeiro, Y.; Couchy, G.; Balabaud, C.; Bioulac-Sage, P.; Pelletier, L.; Rebouissou, S.; Zucman-Rossi, J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47(6):1955-1963; 2008.
29. Ding, L.; Xu, Y.; Zhang, W.; Deng, Y.; Si, M.; Du, Y.; Yao, H.; Liu, X.; Ke, Y.; Si, J.; et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 20(7):784-793; 2010.
30. Wu, W. K.; Lee, C. W.; Cho, C. H.; Fan, D.; Wu, K.; Yu, J.; Sung, J. J. MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene 29(43):5761-5771;2010.
31. Xu, Y.; Deng, Y.; Yan, X.; Zhou, T. Targeting miR-375 in gastric cancer. Expert Opin. Ther. Targets 15(8):961-972; 2011.